Ocriplasmin for Vitreoretinal Diseases

Fibronectin and laminin are clinically relevant plasmin receptors in the eye. Located at the vitreoretinal interface, they are cleaved by ocriplasmin (Microplasmin, ThromboGenics, Iselin, NJ), a novel ophthalmic medication. A series of clinical trials to study ocriplasmin for the treatment of vitreo...

Descripción completa

Detalles Bibliográficos
Autores principales: Tsui, Irena, Pan, Carolyn K., Rahimy, Ehsan, Schwartz, Steven D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2012
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3496214/
https://www.ncbi.nlm.nih.gov/pubmed/23193358
http://dx.doi.org/10.1155/2012/354979
_version_ 1782249616726556672
author Tsui, Irena
Pan, Carolyn K.
Rahimy, Ehsan
Schwartz, Steven D.
author_facet Tsui, Irena
Pan, Carolyn K.
Rahimy, Ehsan
Schwartz, Steven D.
author_sort Tsui, Irena
collection PubMed
description Fibronectin and laminin are clinically relevant plasmin receptors in the eye. Located at the vitreoretinal interface, they are cleaved by ocriplasmin (Microplasmin, ThromboGenics, Iselin, NJ), a novel ophthalmic medication. A series of clinical trials to study ocriplasmin for the treatment of vitreoretinal diseases such as vitreomacular traction, macular hole, and exudative age-related macular degeneration are underway. The results are promising and may impact patient care.
format Online
Article
Text
id pubmed-3496214
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher Hindawi Publishing Corporation
record_format MEDLINE/PubMed
spelling pubmed-34962142012-11-28 Ocriplasmin for Vitreoretinal Diseases Tsui, Irena Pan, Carolyn K. Rahimy, Ehsan Schwartz, Steven D. J Biomed Biotechnol Review Article Fibronectin and laminin are clinically relevant plasmin receptors in the eye. Located at the vitreoretinal interface, they are cleaved by ocriplasmin (Microplasmin, ThromboGenics, Iselin, NJ), a novel ophthalmic medication. A series of clinical trials to study ocriplasmin for the treatment of vitreoretinal diseases such as vitreomacular traction, macular hole, and exudative age-related macular degeneration are underway. The results are promising and may impact patient care. Hindawi Publishing Corporation 2012 2012-10-14 /pmc/articles/PMC3496214/ /pubmed/23193358 http://dx.doi.org/10.1155/2012/354979 Text en Copyright © 2012 Irena Tsui et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review Article
Tsui, Irena
Pan, Carolyn K.
Rahimy, Ehsan
Schwartz, Steven D.
Ocriplasmin for Vitreoretinal Diseases
title Ocriplasmin for Vitreoretinal Diseases
title_full Ocriplasmin for Vitreoretinal Diseases
title_fullStr Ocriplasmin for Vitreoretinal Diseases
title_full_unstemmed Ocriplasmin for Vitreoretinal Diseases
title_short Ocriplasmin for Vitreoretinal Diseases
title_sort ocriplasmin for vitreoretinal diseases
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3496214/
https://www.ncbi.nlm.nih.gov/pubmed/23193358
http://dx.doi.org/10.1155/2012/354979
work_keys_str_mv AT tsuiirena ocriplasminforvitreoretinaldiseases
AT pancarolynk ocriplasminforvitreoretinaldiseases
AT rahimyehsan ocriplasminforvitreoretinaldiseases
AT schwartzstevend ocriplasminforvitreoretinaldiseases

Ejemplares similares